- Home
- AXS vs VTRS Comparison
AXS vs VTRS Comparison
Compare AXS & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXS
- VTRS
- Stock Information
- Founded
- AXS 2001
- VTRS 1961
- Country
- AXS Bermuda
- VTRS United States
- Employees
- AXS N/A
- VTRS N/A
- Industry
- AXS Property-Casualty Insurers
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- AXS Finance
- VTRS Health Care
- Exchange
- AXS Nasdaq
- VTRS Nasdaq
- Market Cap
- AXS 8.1B
- VTRS 9.0B
- IPO Year
- AXS N/A
- VTRS N/A
- Fundamental
- Price
- AXS $103.79
- VTRS $8.79
- Analyst Decision
- AXS Strong Buy
- VTRS Hold
- Analyst Count
- AXS 9
- VTRS 4
- Target Price
- AXS $107.75
- VTRS $10.50
- AVG Volume (30 Days)
- AXS 551.0K
- VTRS 17.6M
- Earning Date
- AXS 04-30-2025
- VTRS 05-08-2025
- Dividend Yield
- AXS 1.70%
- VTRS 5.46%
- EPS Growth
- AXS 54.31
- VTRS N/A
- EPS
- AXS 10.08
- VTRS N/A
- Revenue
- AXS $6,055,200,000.00
- VTRS $14,330,200,000.00
- Revenue This Year
- AXS $4.15
- VTRS N/A
- Revenue Next Year
- AXS $8.03
- VTRS $1.85
- P/E Ratio
- AXS $10.30
- VTRS N/A
- Revenue Growth
- AXS 5.79
- VTRS N/A
- 52 Week Low
- AXS $68.02
- VTRS $6.85
- 52 Week High
- AXS $104.16
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- AXS 62.48
- VTRS 54.57
- Support Level
- AXS $100.69
- VTRS $8.19
- Resistance Level
- AXS $102.91
- VTRS $8.85
- Average True Range (ATR)
- AXS 1.98
- VTRS 0.25
- MACD
- AXS 0.04
- VTRS 0.00
- Stochastic Oscillator
- AXS 93.58
- VTRS 65.22
About AXS Axis Capital Holdings Limited
Axis Capital Holdings Ltd is a specialty underwriter and provider of insurance and reinsurance solutions with operations in Bermuda, the United States ("U.S."), Europe, Singapore, and Canada. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks. The company's segment consists of AXIS Insurance and AXIS Reinsurance. The company generates the majority of its revenue from the Insurance segment. Geographically, the company generates the majority of its revenue from the United States.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.